These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23123934)

  • 1. Garry Neil. Interview by Asher Mullard.
    Neil G
    Nat Rev Drug Discov; 2012 Nov; 11(11):826. PubMed ID: 23123934
    [No Abstract]   [Full Text] [Related]  

  • 2. TransCelerate makes progress.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356586
    [No Abstract]   [Full Text] [Related]  

  • 3. Charles Hugh-Jones. Interview by Asher Mullard.
    Hugh-Jones C
    Nat Rev Drug Discov; 2013 Dec; 12(12):900. PubMed ID: 24287774
    [No Abstract]   [Full Text] [Related]  

  • 4. Geron-Roslin alliance aims broadly at degenerative diseases.
    Fox JL
    Nat Biotechnol; 1999 Jun; 17(6):529-30. PubMed ID: 10385308
    [No Abstract]   [Full Text] [Related]  

  • 5. Busting the billion-dollar myth: how to slash the cost of drug development.
    Maxmen A
    Nature; 2016 Aug; 536(7617):388-90. PubMed ID: 27558048
    [No Abstract]   [Full Text] [Related]  

  • 6. Collaborative effort.
    Novak K
    Nat Rev Cancer; 2002 Sep; 2(9):638. PubMed ID: 12240637
    [No Abstract]   [Full Text] [Related]  

  • 7. AIDS vaccine duo.
    Nature; 2005 Jun; 435(7046):1159. PubMed ID: 15988492
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials in India: balancing economic opportunity with the public health context.
    Dandona L
    Natl Med J India; 2006; 19(2):57-9. PubMed ID: 16756189
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions.
    Matter A; Keller TH
    Drug Discov Today; 2008 Apr; 13(7-8):347-52. PubMed ID: 18405848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paul Brown. Interview by Asher Mullard.
    Brown P
    Nat Rev Drug Discov; 2011 Sep; 10(10):726. PubMed ID: 21959279
    [No Abstract]   [Full Text] [Related]  

  • 11. David Haslam. Interview by Asher Mullard.
    Haslam D
    Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
    [No Abstract]   [Full Text] [Related]  

  • 12. RuiPing Dong. Interview by Asher Mullard.
    Dong R
    Nat Rev Drug Discov; 2012 Feb; 11(2):100. PubMed ID: 22293559
    [No Abstract]   [Full Text] [Related]  

  • 13. An audience with... Victoria G. Hale.
    Hale VG
    Nat Rev Drug Discov; 2005 Nov; 4(11):878. PubMed ID: 16299916
    [No Abstract]   [Full Text] [Related]  

  • 14. Richard Bergström. Interview by Asher Mullard.
    Bergström R
    Nat Rev Drug Discov; 2011 Jun; 10(6):408. PubMed ID: 21629284
    [No Abstract]   [Full Text] [Related]  

  • 15. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 16. Mark McClellan. Interview by Asher Mullard.
    McClellan M
    Nat Rev Drug Discov; 2012 Sep; 11(9):668. PubMed ID: 22935796
    [No Abstract]   [Full Text] [Related]  

  • 17. Creating more paths to hope.
    Hale V
    Newsweek; 2004 Dec; 144(23):80. PubMed ID: 15605728
    [No Abstract]   [Full Text] [Related]  

  • 18. An audience with Guido Rasi. Interview by Asher Mullard.
    Rasi G
    Nat Rev Drug Discov; 2012 Mar; 11(3):182. PubMed ID: 22378260
    [No Abstract]   [Full Text] [Related]  

  • 19. Allocation of control rights and cooperation efficiency in public-private partnerships: theory and evidence from the Chinese pharmaceutical industry.
    Zhang Z; Jia M; Wan D
    Int J Health Care Finance Econ; 2009 Jun; 9(2):169-82. PubMed ID: 19360467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deal watch: co-promotion deals: panacea or poison pill?
    Borshell N; Papp T
    Nat Rev Drug Discov; 2010 Nov; 9(11):831. PubMed ID: 21030991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.